ALK and non-small cell lung carcinoma: Many strategies to treat CNS disease in ALK-positive NSCLC patients have been reported as case reports, such as high-dose crizotinib with a limited intracranial PFS of 1 month (132) and high-dose pemetrexed in combination with high-dose crizotinib with overall stable cerebral disease for 7 months.